Treatment Options for Graves Disease: A Cost-Effectiveness Analysis
Authors:
- Haejin InHIHaejin In
- Elizabeth N. PearceEPElizabeth N. Pearce
- Arthur K. WongAWArthur K. Wong
- James F. BurgessJBJames F. Burgess
- David B. McAnenyDMDavid B. McAneny
- Jennifer E. RosenJRJennifer E. Rosen
- 1 August 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 209 (2) , 170-179e2
Abstract
First-line treatment for Graves disease is frequently 18 months of antithyroid medication (ATM). Controversy exists concerning the next best line of treatment for patients who have failed to achieve euthyroidism; options include lifelong ATM, radioactive iodine (RAI), or total thyroidectomy (TT). We aim to determine the most cost-effective option. We performed a cost-effectiveness analysis comparing these different strategies. Treatment efficacy and complication data were derived from a literature review. Costs were examined from a health-care system perspective using actual Medicare reimbursement rates to an urban university hospital. Outcomes were measured in quality-adjusted life-years (QALY). Costs and effectiveness were converted to present values; all key variables were subjected to sensitivity analysis. TT was the most cost-effective strategy, resulting in a gain of 1.32 QALYs compared with RAI (at an additional cost of 9,594 US dollars) and an incremental cost-effectiveness ratio of 7,240 US dollars/QALY. RAI was the least costly option at 23,600 US dollars but also provided the least QALY (25.08 QALY). Once the cost of TT exceeds 19,300 US dollars, the incremental cost-effectiveness ratio of lifelong ATM and TT reverse and lifelong ATM becomes the more cost-effective strategy at 15,000US dollars/QALY. This is the first formal cost-effectiveness study in the US of the optimal treatment for patients with Graves disease who fail to achieve euthyroidism after 18 months of ATM. Our findings demonstrate that TT is more cost effective than RAI or lifelong ATM in these patients; this continues until the cost of TT becomes > 19,300 US dollars.Keywords
This publication has 35 references indexed in Scilit:
- Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidismSurgery, 2006
- Diagnosis and management of thyrotoxicosisBMJ, 2006
- Radioiodine or Surgery for Toxic Thyroid Adenoma: Dissecting an Important Decision. A Cost-Effectiveness AnalysisThyroid®, 2004
- Antithyroid Drug-Induced Agranulocytosis: Special Reference to Normal White Blood Cell Count AgranulocytosisThyroid®, 2004
- Multicentre study of thyroid nodules in patients with Graves' diseaseBritish Journal of Surgery, 2000
- Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study GroupThe Journal of Clinical Endocrinology & Metabolism, 1996
- The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmö during the period 1970–1974Journal of Internal Medicine, 1991
- Malignant Thyroid Tumors after Iodine-131 TherapyNew England Journal of Medicine, 1980
- Hypothyroidism as a Late Sequela in Patients with Graves' Disease Treated with Antithyroid AgentsJournal of Clinical Investigation, 1979
- Thyroidectomy for HyperthyroidismAnnals of Surgery, 1972